# Leuprolide

Canonical source: https://retacompare.com/encyclopedia/leuprolide

GnRH receptor super-agonist. Continuous receptor activation downregulates GnRH receptors after initial flare, suppressing LH/FSH.

Reference facts

Also known asLupron, EligardCategoryGnRH & ReproductiveMechanism of actionGnRH receptor super-agonist. Continuous receptor activation downregulates GnRH receptors after initial flare, suppressing LH/FSH.TargetsGnRH receptorIndications under research or approvedProstate cancer, Endometriosis, Uterine fibroids, Central precocious pubertyRegulatory status (reference entry)FDA-approved (1985)Half-life~3 hours (depot formulations release over 1-6 months)Sequence notesNonapeptide pyroGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt — D-Leu at position 6 and ethylamide replace native Gly10.Molecular weight (Da)1209Originator / sponsorAbbVie / TolmarFirst reported1973
    Primary References

Lupron Depot FDA label


    Explore research articles about Leuprolide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Lupron Depot FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020517s036_019732s041lbl.pdf